Viva Biotech Holdings Group reported that Viva Shanghai, the primary entity for Viva Biotech’s CRO business, successfully raised nearly $150 million through the transfer of approximately 24% of its equity interest to Temasek, HLC, and True Light. The listed entity of Viva Biotech secured proceeds of approximately $60 million through such financing. The transaction also unveiled the company’s future plan to spin off its CRO business for separate listing in the A-shares market. A...